Skip to content
HOME cell supply ncyte nhp c vcardiomyocytes

Ncyte® NHP-C vCardiomyocytes

Non-Human Primate Cynomolgus iPSC-Derived Ventricular-Like Cardiomyocytes

Cardiac safety assessment demands physiologically relevant, translational models for cross-species comparison. Traditionally, non-human primates (NHPs) have been critical for bridging preclinical and human data. Yet growing ethical concerns, high costs, supply challenges, and shifting regulatory expectations make reliance on live NHP models increasingly unsustainable. Meanwhile, conventional in vitro systems fail to capture NHP biology with sufficient fidelity.

Ncyte® NHP-C vCardiomyocytes are commercially available, high-purity ventricular-like cardiomyocytes derived from cynomolgus iPSCs that closely mimic human cardiac electrophysiology and pharmacology — enabling more predictive, scalable and ethical safety screening across species.

cardiac
Benefits
  • High purity, NHP cynomolgus ventricular-like cardiomyocytes
  • Powerful tool for cross-species cardiac research
  • Suitable for 2-day pre-culture and plate-ready
  • Visible beating clusters within 72 hours of seeding
  • Fully functional and electrophysiologically active
  • Ideal for electrophysiology and cardiotoxicity testing

Are you ready for more ethical and translational preclinical safety research?

Do you need a large volume or custom cell model?

Translational Cardiovascular Research Stems From Ncyte® NHP-C vCardiomyocytes

As the only iPSC-derived NHP ventricular cardiomyocytes on the market, Ncyte® NHP-C vCardiomyocytes enhance the translational value of cardiovascular research while meeting the FDA’s evolving expectations on the use of live NHPs.

By enabling direct comparison between human and non-human primate cardiac cells in vitro, they: 

  • Support cross-species mechanistic studies that validate findings between preclinical and human systems 
  • Improve cardiotoxicity risk assessment in alignment with regulatory expectations 
  • Provide a more predictive non-clinical model that lowers drug development risk

Product Specifications

Identity markers

≥ 70% cTnT+ cells by flow cytometry at thawing and day 2 after thawing according to the user guide

Size

≥ 4M viable cells at thawing according to user guide​ ≥ 1M viable cells at day 2 after thawing according to user guide​

Quality control

Cell count, viability, identity (flow cytometry), functionality (MEA: dofetilide, nifedipine, isoproterenol), mycoplasma​

Format

Cryopreserved cells​

Donor

Male

Reprogramming method

Ectopic expression of reprogramming factors using episomes

Shipping conditions

Dry shipper, -180° C to -135° C

Storage conditions

Vapor phase of liquid nitrogen

Technical Data

Identity Applications Electrophysiological Activity Functional Testing of Cell Responses to Drug Candidates

Ncyte® NHP-C vCardiomyocytes are characterized by flow cytometry to ensure a purity of ≥ 70% cardiac Troponin T (cTnT) positive cells at thawing and 2 days after thawing. 

Histograms of cTnT fluorescence signal and its antibody control at Day 0 (Figure C) and Day 2 after thawing (Figure D).

Ncyte® NHP-C vCardiomyocytes are a versatile and scalable tool for: 

  • Cardiotoxicity screening
  • Electrophysiological assays (e.g., MEA)
  • Drug development (from hit to lead optimization)
  • Mechanistic and disease modeling studies
  • Regenerative medicine research 
Immunofluorescence staining of Ncyte® NHP-C vCardiomyocytes: Alpha-actinin (Red), cardiac Troponin T (Green) and DAPI (Blue). 40x magnification.

Ncyte® NHP-C vCardiomyocytes are a physiologically relevant model for the phenotypic study of cardiac diseases. They feature well aligned myofibrils and intact structural sarcomere organization, enabling robust pacing and electrophysiological readouts.  

 

Ncyte® NHP-C vCardiomyocytes also present a robust electrode coverage and a relatively slow and uniform beating rate. 

 

Get a closer look at electrophysiology data in our Ncyte® NHP-C vCardiomyocytes fact sheet.  

 

Download Fact Sheet

 

Analysis of over 50 beats demonstrates high stability and consistent beating patterns.

These cells are highly responsive to pharmacological modulation such as adrenergic stimulation with isoproterenol and two ion channel blockers such as nifedipine (L-type calcium channel blocker) and dofetilide (hERG channel blocker). They can therefore be utilized in functional assays such as imaging, impedance, capacitance, contractility, metabolic profiling and cell viability. They are also valuable for biomarker identification.  

Leverage Ncardia’s custom iPSC services to de-risk candidate selection and advance your drug discovery pipeline.  

Explore iPSC Services

 

Combine Ncyte® NHP-C vCardiomyocytes with our validated cardiotoxicity assays for a comprehensive evaluation of cardiac safety.

Explore Ready-to-Use Assays
Exposure to Isoproterenol causes an acute increase in beat rate in Ncyte® NHP-C vCardiomyocytes. Data presented as mean ± SD (n=3) of the % change to baseline recordings for each well.
Representative MEA traces immediately after exposure to increased dosage of isoproterenol, showing shorter beat periods after Isoproterenol treatment in Ncyte® NHP-C vCardiomyocytes.
Representative trace after 30-minute exposure to Dofetilide, a hERG (Ikr) channel blocker, at concentrations ≥ 10 nM, showing notable arrhythmias in Ncyte® NHP-C vCardiomyocytes.
A 30-minute exposure to increased dosage of Nifedipine, an L-type calcium channel blocker, causes beating arrest in Ncyte® NHP-C vCardiomyocytes.
Ncyte® NHP-C vCardiomyocytes Information and Application

Certificates of analysis are available upon request via support@ncardia.com

Related Cell Models
Questions about our cell models?

By combining advanced iPSC expertise, versatile assay platforms and a proven track record of modeling human disease biology, we empower drug developers to make smarter, faster decisions in early-stage research.